137 related articles for article (PubMed ID: 28447926)
1. Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report.
Abbassi M; Riley R; Malkin M; Tang Y; Rajendran B; Yazbeck V
Exp Clin Transplant; 2019 Feb; 17(1):111-114. PubMed ID: 28447926
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant Lymphoproliferative Disorder Manifesting as Intestinal Epstein-Barr Virus-Positive Anaplastic Large-Cell Lymphoma in an Adult Renal Transplant Recipient.
Börcek P; Özdemir BH; Özgün G; Haberal M
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):64-66. PubMed ID: 27805515
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy.
Said-Conti V; Amrolia PJ; Gaze MN; Stoneham S; Sebire N; Shroff R; Marks SD
Pediatr Nephrol; 2013 Oct; 28(10):2053-6. PubMed ID: 23743853
[TBL] [Abstract][Full Text] [Related]
4. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
7. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
Xu H; Rewerska J; Aardsma N; Slavin K; Valyi-Nagy T; Ni H
Folia Neuropathol; 2017; 55(3):221-226. PubMed ID: 28984115
[TBL] [Abstract][Full Text] [Related]
8. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
Banks CA; Meier JD; Stallworth CR; White DR
Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.
Valencia-Sanchez C; Steenerson KK; Kelemen K; Orenstein R; Kusne S; Grill MF
J Neurovirol; 2019 Apr; 25(2):280-283. PubMed ID: 30607891
[TBL] [Abstract][Full Text] [Related]
10. Conservative management of post-transplant central nervous system lymphoma.
Valavoor SH; Ashraf Z; Narwal R; Ratnam S
Int Urol Nephrol; 2013 Aug; 45(4):1219-22. PubMed ID: 22476860
[TBL] [Abstract][Full Text] [Related]
11. Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder.
Azarpira N; Torabineghad S; Rakei M
Exp Clin Transplant; 2009 Mar; 7(1):58-61. PubMed ID: 19364315
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma.
Degen D; Kanellis J; Hughes P; Barit D; Ierino F
Nephrology (Carlton); 2016 Jun; 21(6):528. PubMed ID: 27188412
[No Abstract] [Full Text] [Related]
13. Bone marrow involvement by lymphoproliferative disorders after solid-organ transplant.
Akar Özkan E; Özdemir BH; Yılmaz Akçay E; Terzi A; Karakuş S; Haberal M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():183-7. PubMed ID: 25894151
[TBL] [Abstract][Full Text] [Related]
14. B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.
Sundin A; Grzywacz BJ; Yohe S; Linden MA; Courville EL
Hum Pathol; 2017 Mar; 61():140-147. PubMed ID: 27993575
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant lymphoproliferative disorder with lung involvement in a renal transplant recipient.
Mirza EI; Mutluay R; Suyani E; Okyay GU; Akyurek N; Aki SZ; Derici U; Arinsoy T
Exp Clin Transplant; 2011 Dec; 9(6):425-8. PubMed ID: 22142053
[TBL] [Abstract][Full Text] [Related]
16. Primary Central Nervous System Posttransplant Lymphoproliferative Disorder After Kidney Transplant.
Stone T; Eskandari R; Baker T; Antonucci M; Yazdani M
J Pediatr Hematol Oncol; 2021 May; 43(4):144-146. PubMed ID: 32398602
[TBL] [Abstract][Full Text] [Related]
17. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.
Dugan JP; Haverkos BM; Villagomez L; Martin LK; Lustberg M; Patton J; Martin M; Huang Y; Nuovo G; Yan F; Cavaliere R; Fingeroth J; Kenney SC; Ambinder RF; Lozanski G; Porcu P; Caligiuri MA; Baiocchi RA
Clin Cancer Res; 2018 Jul; 24(14):3273-3281. PubMed ID: 29632007
[No Abstract] [Full Text] [Related]
18. Primary Central Nervous System Hodgkin Lymphoma-Like Posttransplant Lymphoproliferative Disorder.
Hori YS; Nagakita K; Ebisudani Y; Aoi M; Fukuhara T; Shinno Y
World Neurosurg; 2018 Jun; 114():230-234. PubMed ID: 29609086
[TBL] [Abstract][Full Text] [Related]
19. Burkitt lymphoma after transplant: an aggressive lymphoproliferative disease.
Akar Özkan E; Özdemir BH; Akdur A; Deniz EE; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():136-8. PubMed ID: 24635811
[TBL] [Abstract][Full Text] [Related]
20. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
